Industry
Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 29, 2024 | 9:36 am
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 5:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 10:19 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 7:25 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 3:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.